

To: jena.de[5.1.2e] @uni-tuebingen.de[5.1.2e] @uni-tuebingen.de[5.1.2e] @med.uni-jena.de[5.1.2e] @lmc.nl[5.1.2e] @lmc.nl[5.1.2e] @pei.de[5.1.2e] @pei.de[5.1.2e] @pei.de[5.1.2e] @rvm.nl[5.1.2e] @rvm.nl[5.1.2e] @rvm.nl[5.1.2e] @sciensano.be[5.1.2e] @sciensano.be[5.1.2e] @sciensano.be[5.1.2e] @sclavo.org[5.1.2e] @sclavo.org[5.1.2e] @fondazioneclavo.org[5.1.2e] @fondazioneclavo.org[5.1.2e] @microbio.gu.se[5.1.2e] @microbio.gu.se[5.1.2e] @uib.no[5.1.2e] @uib.no[5.1.2e] @uib.no[5.1.2e] @uib.no[5.1.2e] @rug.nl[5.1.2e] @rug.nl[5.1.2e] @umcg.nl[5.1.2e] @umcg.nl[5.1.2e] @unisi.it[5.1.2e] @unisi.it[5.1.2e] @unisi.it[5.1.2e] @unisi.it[5.1.2e] @nottingham.ac.uk[5.1.2e] @nottingham.ac.uk[5.1.2e] @uu.nl[5.1.2e] @uu.nl[5.1.2e] @uu.nl[5.1.2e] @uu.nl[5.1.2e] @biozentrum.uni-wuerzburg.de[5.1.2e] @biozentrum.uni-wuerzburg.de[5.1.2e] @uni-wuerzburg.de[5.1.2e] @vismederi.com[5.1.2e] @vismederi.com[5.1.2e] @vismederi.com[5.1.2e] @sanofi.com[5.1.2e] @euvaccine.eu[5.1.2e]

Cc: [REDACTED] 5.1.2e [REDACTED] 5.1.2e [REDACTED] @sanofi.com]; [REDACTED] 5.1.2e [REDACTED] 5.1.2e [REDACTED] @euvaccine.eu]

From: 5.1.2e

Sent: Wed 12/2/2020 12:08:28 PM

Subject: FW: Inno4Vac HoT meeting: Action for ST Leaders/coleaders

Received: Wed 12/2/2020 12:08:31 PM

201202_EFPIA_Inno4Vac_Timelines-CA.pptx

201202 Inno4Vac HoT V.1.93-Clean.docx

Dear ST3-Inno4Vac partners,

While waiting for our proposal to be reviewed and even though it's not 100% sure it will be granted, we would like to start working on the Consortium Agreement. A stepwise approach will be followed, with a CA draft set up by a writing, consulting and core group, before going to all partners for careful review (see timelines).

At the moment a Heads of Terms (HoT, see doc) document is drafted, outlining important matters, such as intellectual property background, later to go into the legal language of the CA document. We are now trying to inventorize this background per partner.

Can I please ask you to provide me, **per institute**, with **input to go into this Table A3** of the current HoT document?

It is short notice, but I was asked as ST3 lead to combine the input for ST3 by next Friday. This will not be the only moment you can specify this important information, but the earlier we know the better.

Thank you very much in advance.

Kind regards,

5.1.2e

5.1.2e 5.1.2e 1,2

Centre for Immunology of Infectious Diseases and Vaccines | National Institute for Public Health and the Environment (RIVM) | Antonie van Leeuwenhoeklaan 9 | PO box 1 | 3720 BA BILTHOVEN | The Netherlands

²Infectious Diseases & Immunology | Dept. Biomolecular Health Sciences | Faculty of Veterinary Medicine | Utrecht University | Yalelaan 1 | PO box 80165 | 3508 TD UTRECHT | The Netherlands

T: 5.1.2e | M: 5.1.2e | E: 5.1.2e @rivm.nl

From: 5.1.2e <5.1.2e@euvaccine.eu>

Sent: woensdag 2 december 2020 08:13

To: 5.1.2e @gsk.com>; 5.1.2e <5.1.2e@sanofi.com>; 5.1.2e <5.1.2e@unisi.it>; 5.1.2e <5.1.2e@medisin.uio.no>; 5.1.2e <5.1.2e@gsk.com>; 5.1.2e <5.1.2e@medisin.uio.no>; 5.1.2e <5.1.2e@sanofi.com>; 5.1.2e <5.1.2e@lumc.nl>; 5.1.2e <5.1.2e@imperial.ac.uk>; 5.1.2e <5.1.2e@sanofi.com>; 5.1.2e <5.1.2e@rivm.nl>; 5.1.2e <5.1.2e@pei.de>; 5.1.2e <5.1.2e@ucl.ac.uk>; 5.1.2e <5.1.2e@euvaccine.eu>; 5.1.2e <5.1.2e@sanofi.com>; 5.1.2e <5.1.2e@gsk.com>; 5.1.2e <5.1.2e@gsk.com>; 5.1.2e <5.1.2e@euvaccine.eu>; 5.1.2e <5.1.2e@euvaccine.eu>

5.1.2e

Subject: Inno4Vac HoT meeting: Action for ST Leaders/coleaders

Dear All,

Please find in attachment the updated slide set (as discussed during our meeting on Monday) together with the updated HoT document (also as discussed during the meeting).

CA agreement drafting:

Level 1: writing team	GSK + EVI
Level 2: consultation team (UK)	SP + SVA + Takeda + CureVac + ST Leaders (UiO (No), LUMC (NI), RIVM (NI), UCL (UK))
Level 3: core group	level 1 + level 2 Centre for Human Drug Research - CHDR (NL) Imperial College London - ICL (UK) Danmarks Teknishe Universitet – DTU (DK) Universitetet i Bergen – (UiB) (No)
Level 4: full consortium	All partners

HoT Document:

There is an action for ST Leaders and coleads to give their input in A3 Table background information by EOB Friday 4 December.

The final submitted proposal can be found in sharepoint ()

5.1.2h

5.1.2h

In order to do so ST

leaders/coleads are free to share this document within their ST group. During the weekend all information will be put together, so we can share an updated version on Monday (7 December) to all consortium partners. A meeting with all partners will be scheduled on Friday 11 December to finalise the HoT document.

In case of questions, or if you need further support, please do not hesitate to contact me.

Kind regards,

5.1.2e

5.1.2e

5.1.2e

Mobile: +49

5.1.2e

5.1.2e

@euvaccine.eu

European Vaccine Initiative
UniversitätsKlinikum Heidelberg
Voßstraße 2, Geb. 4040
69115 Heidelberg, Germany
Website: www.euvaccine.eu